TC
ARIA

TFS Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

TFS Capital’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-297,835
Closed -$2.45M – 1230
2015
Q1 		$2.45M Buy
+297,835
New +$2.2M 0.24% 96
2014
Q1 		– Sell
-40,029
Closed -$273K – 1754
2013
Q4 		$273K Buy
40,029
+23,920
+148% +$129K 0.01% 1140
2013
Q3 		$296K Buy
+16,109
New +$313K 0.01% 1105

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

TFS Capital's ARIA Position: Q2 2015 in Review

TFS Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2015, closing a stake of 297,835 shares — an estimated $2.45M sold.

TFS Capital first reported a position in ARIA in Q3 2013 and held it in 3 quarters. The position peaked at $2.45M in Q1 2015. 177 funds tracked by Wall St. Rank hold ARIA as of Q2 2015.

  • TFS Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • TFS Capital sold 297,835 Ariad Pharmaceuticals Inc shares in Q2 2015, an estimated $2.45M.
  • TFS Capital first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 3 quarters.
  • TFS Capital's Ariad Pharmaceuticals Inc position peaked at $2.45M in Q1 2015.
  • 177 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2015.

Based on TFS Capital's 13F filing for Q2 2015, filed 5 Aug 2015.